API-59CJ-Ome hydrate

• 产品号: A8979
• 分子式: C21H24N2O4
• 分子量: 368.42626
• 纯 度: ≥98% (HPLC)
• 保 存: under inert gas

产品别名

• 标题: API-59CJ-Ome hydrate
• IUPAC标准名: 9-methoxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium acetate hydrate
• IUPAC传统名: 9-methoxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium acetate hydrate
• 别名: 9-Methoxy-2-methylellipticinium acetate hydrate

产品登记号

• EC号: 308-789-6
• PubChem SID: 24724403
• MDL号: MFCD08705317

产品性质

• Empirical Formula (Hill Notation): C19H19N2O · C2H3O2 · xH2O
• 纯度: ≥98% (HPLC)
• 外观: red lyophilized powder
• 溶解度: H2O: soluble1 mg/mL
• 溶解度: DMSO: ≥2 mg/mL, clear, dark red (with 5 min sonication)
• GHS警示词: Warning
• GHS危险声明: H319
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• GHS警示性声明: P305 + P351 + P338
• 保存条件: under inert gas
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
API-59CJ-Ome hydrate is a highly selective Akt/PKB inhibitor. The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor is mutated in 40-50% of human endometrial cancers. PTEN exerts its effects in part via inhibition of the antiapoptotic protein AKT. The endometrial cancer cell lines that express PTEN mutations show high levels of phosphorylated AKT and high AKT kinase activity. The endometrial cancer cell lines that express wild-type PTEN have little phosphorylated AKT and AKT kinase activity. API-59CJ-OMe inhibits AKT kinase activity and induces apoptosis in the cell lines with high AKT activity, but has little effect on cells without AKT activity. API-59CJ-OMe may therefore have therapeutic potential for those endometrial cancers that harbor PTEN mutations and AKT activation.

详细说明 (简体中文)

Biochem/physiol Actions
API-59CJ-Ome hydrate is a highly selective Akt/PKB inhibitor. The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor is mutated in 40-50% of human endometrial cancers. PTEN exerts its effects in part via inhibition of the antiapoptotic protein AKT. The endometrial cancer cell lines that express PTEN mutations show high levels of phosphorylated AKT and high AKT kinase activity. The endometrial cancer cell lines that express wild-type PTEN have little phosphorylated AKT and AKT kinase activity. API-59CJ-OMe inhibits AKT kinase activity and induces apoptosis in the cell lines with high AKT activity, but has little effect on cells without AKT activity. API-59CJ-OMe may therefore have therapeutic potential for those endometrial cancers that harbor PTEN mutations and AKT activation.